Our Story

Our Story

Reditus celebrates expansion, looks to the future

Dr. Aaron Rossi’s vision of a full-service reference laboratory in Pekin, Ill., is taking form one test at a time.

Dr. Rossi founded Reditus Laboratories and opened the doors in June of 2019. The lab started with anatomic pathology, histology and then added PCR testing for infectious disease in December 2019. Reditus had ten laboratory personnel employed at the end of 2019. Today Reditus has over 300 employees and is continuing its pursuit of laboratory excellence.

Reditus has expanded its testing capabilities into areas of infectious disease, Next-Gen sequencing, hematopathology, flow cytometry, and much more. Specifically, with the addition of two Illumina 550DX sequencers and the Illumina NextSeq2000, Reditus has now validated its oncology platform to become one of the few labs in the country with this offering.
Reditus recently just finished all phases of remodel and new construction. The lab is now over 40,000 square feet.

To quickly and accurately diagnose soft tissue and wound infections, Reditus acquired its first real-time reverse transcriptase polymerase chain reaction (RT-PCR) machine in December 2019. Meanwhile, SARS-CoV-2 (COVID-19) had entered Illinois. Since April 2020, Reditus has performed more than 3.5 million tests for COVID-19.

Even with the staggering numbers, Reditus remains focused on quality. Reditus is accredited by the College of American Pathologists (CAPs). The CAP Laboratory Accreditation Program is a rigorous accreditation process certifying that Reditus meets standards in areas such as laboratory safety, procedures, training, documentation, and personnel qualifications. Reditus met all the standards with a perfect score and zero deficiencies.

As COVID-19 testing continues, Reditus has expanded into sequencing of randomly selected positive COVID-19 samples to identify variants, which are more contagious and may have potential resistance to the vaccines. Reditus shares this data with Illinois Department of Public Health, the U.S. Centers for Disease Control and Prevention and GISAID, a global initiative that provides access to genomic data of influenza viruses and COVID-19.

Reditus also is expanding into offering a FluV19 At-Home Collection Kit, in which customers will be able to collect their own specimen from the comfort of their home and overnight the sample to Reditus. Reditus will test the sample for Influenza A and B as well as COVID-19. Results will be available to the customer 24 hours after the lab receives the specimens.

“I am proud of our growth and gratified that we have been able to develop a full-service lab in Central Illinois,” Dr. Rossi said. “But it’s not about the numbers. My goal when opening Reditus Laboratories was to become one of the nation’s top diagnostic laboratories. We are well on our way to accomplishing this, even during a pandemic, which speaks volumes to the quality and dedication of our staff, who ensure that the patient always comes first.”

Ways We Test

Reditus FluV-19 At-Home
Test Kit

View

Pathology Group

We bring pathology services to 16 healthcare facilities in central Illinois and eastern Iowa.

Partner Physicians

We provide results and vital information to physicians in diagnosing illness.

Ways We Test

Reditus FluV-19 At-Home
Test Kit

View

Pathology Group

We bring pathology services to 16 healthcare facilities in central Illinois and eastern Iowa.

Partner Physicians

We provide results and vital information to physicians in diagnosing illness.